Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
1,100 USD +1.83% Intraday chart for Regeneron Pharmaceuticals, Inc. +6.36% +25.25%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 MT
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050 MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,232 From $1,229, Keeps Outperform Rating MT
Regeneron Expects Earnings Hit After $24 Million R&D Charge DJ
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval MT
Sanofi obtains EU approval for Dupixent RE
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease DJ
EU approves Sanofi's Dupixent for 'smoker's lungs' RE
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 1000 Dynamic Index CI
Regeneron Gets European Health Agency Committee's Positive Opinion for Conditional Marketing Authorization of Lymphoma Drug Candidate Odronextamab MT
Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab DJ
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma CI
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study MT
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine CI
FDA approves Verona Pharma's therapy for 'smoker's lungs' RE
Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia RE
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained MT
Declaration of Voting Results by Regeneron Pharmaceuticals, Inc CI
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050 MT
Regeneron Pharmaceuticals Says 50% of Patients in Multiple Myeloma Therapy Study Achieved Complete Response MT
Chart Regeneron Pharmaceuticals, Inc.
More charts
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,100 USD
Average target price
1,063 USD
Spread / Average Target
-3.36%
Consensus
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.
  5. Regeneron, Sanofi Gain FDA Approval for Kevzara to Treat Juvenile Idiopathic Arthritis